MELISSA VEIL: Open Payments
NPI 1225426943 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,652 in 71 payments from 14 companies in 2025. Trend: 2023 $49 · 2024 $463 · 2025 $1,652
Food & beverage: $1,568Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $642 |
| Madrigal Pharmaceuticals | 5 | $169 |
| Janssen Biotech, Inc. | 6 | $168 |
| Aimmune Therapeutics, Inc. | 5 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| QOL Medical, LLC | 3 | $79 |
| Ipsen Biopharmaceuticals, Inc | 2 | $66 |
| Intercept Pharmaceuticals, Inc. | 3 | $57 |
| Lilly USA, LLC | 2 | $51 |
| PFIZER INC. | 2 | $49 |
Products named: RINVOQ, SKYRIZI, REZDIFFRA, TREMFYA, Sucraid, ZENPEP, VOWST, ENTYVIO.
Industry payments across NV — which companies pay providers there.
